Download our Atlas H&E-TME validation benchmarks summary for a detailed breakdown of Atlas H&E-TME performance data for specific cancer types, tissue segments, and cell classes.
Rediscovering Known Biology: Validating the Aignostics-Bayer Target ID Platform
29.4.2026
Discover how our Target ID Platform independently rediscovered NRF2 pathway activation in LUSC without any prior knowledge of pathway biology during model training.
At Aignostics, we're transforming complex biomedical data into actionable insights that drive innovation in healthcare. Stay connected with us and be the first to learn how we’re shaping the future of medicine through data-driven solutions.